ID   DRO
AC   CVCL_6286
SY   DRO-90-1; DRO 90-1; DRO90-1; DRO-90; RO 90-D-1; UCLA RO 90-D-1
DR   BioSample; SAMN03151608
DR   BioSample; SAMN03151609
DR   cancercelllines; CVCL_6286
DR   Cosmic; 886551
DR   Cosmic; 888278
DR   Cosmic; 913249
DR   Cosmic; 1155330
DR   Wikidata; Q54831419
RX   PubMed=8871538;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a A-375 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland anaplastic carcinoma.
CC   From: Juillard G.J.-F.; University of California, Los Angeles; Los Angeles; USA.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00188.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): PubMed=18713817; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,14
ST   D16S539: 9
ST   D18S51: 12,17
ST   D21S11: 29,30
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 9
ST   D8S1179: 11,14
ST   FGA: 20,23
ST   TH01: 8
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=8871538; DOI=10.1007/BF00128960;
RA   Boghaert E.R., Ain K.B., Taylor K.D., Greenberg V.L., Fowler C.,
RA   Zimmer S.G.;
RT   "Quantitative and qualitative differences in growth, invasion and lung
RT   colonization of an anaplastic and a papillary human thyroid cancer
RT   cell line in vitro and in vivo.";
RL   Clin. Exp. Metastasis 14:440-450(1996).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//